NCT01493960 - The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients | Biotech Hunter

Enrollment

131

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

March 31, 2014

Conditions

Colitis, Ulcerative

Interventions

DRUG

Cobitolimod

30 mg rectal dose at week 0 and 4

DRUG

Placebo

Rectal dose at week 0 and 4

Trial Locations (37)

Unknown

Site 402, Hradec Králové

Site 404, Hradec Králové

Site 406, Ostrava

Site 407, Ostrava

Site 405, Prague

Site 409, Prague

Site 403, Slaný

Site 702, Pierre-Bénite

Site 501, Berlin

Site 508, Bottrop

Site 514, Erlangen

Site 510, Frankfurt

Site 509, Freiburg im Breisgau

Site 504, Hanover

Site 511, Herne

Site 503, Jena

Site 507, Regensburg

Site 502, Stade

Site 513, Stuttgart

Site 205, Békéscsaba

Site 204, Budapest

Site 207, Budapest

Site 203, Kaposvár

Site 202, Szekszárd

Site 302, Rome

Site 304, Rome

Site 604, Krakow

Site 605, Lodz

Site 607, Lodz

Site 606, Rzeszów

Site 601, Warsaw

Site 602, Warsaw

Site 603, Warsaw

Site 104, Edinburgh

Site 102, London

Site 103, Norwich

Site 101, Nottingham